1. Lu, C. Y., Marcucio, R., & Miclau, T. (2006). Assessing angiogenesis during fracture healing. Iowa Orthopaedic Journal, 26, 17–26.
2. Seregin, S. S., & Amalfitano, A. (2009). Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors. Expert Opinion on Biological Therapy, 9, 1521–1531.
3. Fiorenzo, P., Mongiardi, M. P., Dimitri, D., et al. (2010). HIF1-positive and HIF1-negative glioblastoma cells compete in vitro but cooperate in tumor growth in vivo. International Journal of Oncology, 36, 785–791.
4. Giatromanolaki, A., Fiska, A., Pitsiava, D., et al. (2009). Erythropoietin receptors in endometrial carcinoma as related to HIF1{alpha} and VEGF expression. In Vivo, 23, 699–703.
5. Semenza, G. L. (2007). Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discovery Today, 12, 853–859.